checkAd

    EQS-News  151  0 Kommentare Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome - Seite 5


     
    End of News EQS Group News Service

    1187401  22.04.2021 

    fncls.ssp?fn=show_t_gif&application_id=1187401&application_name=news&site_id=wallstreet

    Lesen Sie auch


    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 5 von 5

    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-News Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome - Seite 5 EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome 22.04.2021 / 07:00 Relief …